Stay updated with breaking news from Lugano Classification. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
21.12.2023 - Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has approved a label update for Yescarta (axicabtagene ciloleucel) to include the overall survival (OS) primary analysis from the landmark Phase ...
– First Ever Prospective Phase 2 Study to Evaluate CAR T-Cell Therapy as First-Line Therapy Reads Out Three-Year Follow-Up Analysis – – At Median Follow-Up of 40.9 Months, Patients Treated...
Read trending news, stories and press releases from PMN Wire News about Canadian and international businesses.
Phase 2 primary analysis results presented in ASH oral session demonstrated a 52% objective response rate , with 31% achieving a complete response Results from a Phase 1 expansion cohort showed a...
Phase 2 primary analysis results presented in ASH oral session demonstrated a 52% objective response rate , with 31% achieving a complete response Results from a Phase 1 expansion cohort showed a...